US Patent

US11612594 — Methods of treating Fabry patients having renal impairment

Composition of Matter · Assigned to Amicus Therapeutics Inc · Expires 2038-05-30 · 12y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects methods for treating Fabry disease in patients with certain genetic mutations, using migalastat hydrochloride administered every other day.

USPTO Abstract

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

Drugs covered by this patent

Patent Metadata

Patent number
US11612594
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-05-30
Drug substance claim
Yes
Drug product claim
No
Assignee
Amicus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.